Vericel (VCEL) Current Deferred Revenue (2015 - 2018)
Vericel (VCEL) posted Current Deferred Revenue of $566000.0 for Q4 2018, up 5.99% sequentially from $534000.0 in Q3 2018, and up 34.76% YoY from $420000.0 in Q4 2017.
Vericel (VCEL) Current Deferred Revenue (2015 - 2018) Analysis & Trends
Vericel has reported Current Deferred Revenue for 4 years, with the latest figure at $566000.0 in Q4 2018.
- Quarterly Current Deferred Revenue rose 34.76% year-over-year to $566000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $566000.0 (up 34.76% YoY) and the FY2018 annual result came in at $566000.0, up 34.76% from the prior year.
- Current Deferred Revenue improved to $566000.0 in Q4 2018 per VCEL's latest filing, from $534000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $566000.0 in Q4 2018 and troughed at $3000.0 in Q4 2016.
- A 4-year average of $362444.4 and a median of $426000.0 in 2018 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue slumped 97.46% in 2016, then surged 13900.0% in 2017.
- Over 4 years, Current Deferred Revenue stood at $118000.0 in 2015, then plunged by 97.46% to $3000.0 in 2016, then soared by 13900.0% to $420000.0 in 2017, then surged by 34.76% to $566000.0 in 2018.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $566000.0, $534000.0, and $503000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 566,000.00 |
| Sep 30, 2018 | 534,000.00 |
| Jun 30, 2018 | 503,000.00 |
| Mar 31, 2018 | 426,000.00 |
| Dec 31, 2017 | 420,000.00 |
| Dec 31, 2016 | 3,000.00 |
| Sep 30, 2016 | 232,000.00 |
| Jun 30, 2016 | 460,000.00 |
| Dec 31, 2015 | 118,000.00 |